Patents Examined by Deepak Rao
  • Substituted benzylpyrazoles
    Patent number: 9260412
    Abstract: Compounds of formula (I) and their use as pharmaceutical.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: February 16, 2016
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marion Hitchcock, Anne Mengel, Anja Richter, Hans Briem, Knut Eis, Vera Pütter, Gerhard Siemeister, Stefan Prechtl, Amaury Ernesto Fernández-Montalván, Christian Stegmann, Simon Holton, Mark Jean Gnoth, Cornelia Preuβe
  • GLP-1 receptor modulators
    Patent number: 9260427
    Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: February 16, 2016
    Assignee: Receptos, Inc.
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
  • Process of preparing alcaftadine
    Patent number: 9255105
    Abstract: The present invention is related to a substantially pure compound of structural formula (VIII), a process for the purification of a compound of structural formula (VIII) and an improved process of preparing an alcaftadine compound of structural formula (I).
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 9, 2016
    Assignee: ENALTEC LABS PRIVATE LIMITED
    Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
  • Inhibitors of lysine specific demethylase-1
    Patent number: 9255097
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 9, 2016
    Assignee: QUANTICEL PHARMACEUTICALS, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Compounds and therapeutic use thereof for protein kinase inhibition
    Patent number: 9249154
    Abstract: Novel compound having the following formula: Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 2, 2016
    Inventor: Zhanggui Wu
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 9248190
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: February 2, 2016
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • Sulfilimine and sulphoxide methods for producing festinavir
    Patent number: 9249171
    Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: February 2, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Adrian Ortiz, Tamas Benkovics, Zhongping Shi, Prashant P. Deshpande, Zhiwei Guo, David R. Kronenthal, Chris Sfouggatakis
  • Process for preparation of amorphous form of dasatinib
    Patent number: 9249134
    Abstract: A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 ° C. or 60% at 25 ° C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I).
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: February 2, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Kumar Kamlesh Singh, Nikhil Amar Singh, Amol Kashinath Patil
  • Trk-inhibiting compound
    Patent number: 9242977
    Abstract: An object of the present invention is to provide a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I): (wherein all symbols represent the same meanings as described in the specification), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: January 26, 2016
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Masahiro Ikura, Masato Higashino, Maki Iwahashi, Kazuya Hashimura
  • Biaryl amide compounds as kinase inhibitors
    Patent number: 9242969
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: January 26, 2016
    Assignee: Novartis AG
    Inventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
  • FN14 antagonists and therapeutic uses thereof
    Patent number: 9238034
    Abstract: The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (Fn14) antagonists to modulate activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of Fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations Fn14 antagonists and chemotherapeutic agents.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 19, 2016
    Assignee: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Nhan Tran, Nathalie Meurice, Harshil Dhruv
  • VEGFR3 inhibitors
    Patent number: 9238644
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 19, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • Benzene sulfonamide thiazole and oxazole compounds
    Patent number: 9233956
    Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 12, 2016
    Assignee: Novartis AG
    Inventor: Tara Renae Rheault
  • 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
    Patent number: 9221798
    Abstract: Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by natural or variant tyrosine kinase. Also provided are preparation methods and uses of the compounds.
    Type: Grant
    Filed: September 5, 2011
    Date of Patent: December 29, 2015
    Assignee: Zhejian Hisun Pharmaceutical Co., Ltd.
    Inventors: Yili Ding, Xuan Yang, Qingyan Yan, Hua Bai, Lifeng Cai, Kenneth Smith, Jian Chai
  • Heteroaryl inhibitors of PDE4
    Patent number: 9221843
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: December 29, 2015
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
  • 5-fluoro pyrimidine derivatives
    Patent number: 9204653
    Abstract: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: December 8, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Timothy Boebel, Kristy Bryan, Carla J. R. Klittich, Beth Lorsbach, Timothy P. Martin, Mark A. Pobanz, Michael T. Sullenberger, Jeffery D. Webster, Chenglin Yao, W. John Owen
  • 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
    Patent number: 9206181
    Abstract: The present invention related to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: (Ia) in free base or acid addition salt form, to processes for their production, to pharmaceutical compositions comprising them and their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and neurodegenerative disorders.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: December 8, 2015
    Assignee: Novartis AG
    Inventors: Mathias Frederiksen, Dominik Feuerbach, Konstanze Hurth, Manuel Koller, Bernard Lucien Roy
  • Arylethynyl pyrimidines
    Patent number: 9199971
    Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is hydrogen or halogen; R2 is C1-3-alkyl or —(CH2)n—O—CH3; n is 2 or 3; m is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) with improved properties for the treatment of schizophrenia, cognitive diseases, fragile X syndrome or autism.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: December 1, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Georg Jaeschke, Lothar Lindemann, Heinz Stadler, Eric Vieira
  • Triazolyl PDE10 inhibitors
    Patent number: 9200001
    Abstract: The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: December 1, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, Vadim Y. Dudkin, June J. Kim, Scott D. Kuduk, Carol A. McVean, Thomas Reger, Justin T. Sheen, Thomas Steele
  • Substituted azaheterocycles for the treatment of cancer
    Patent number: 9199962
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 1, 2015
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Nadia Brugger, Kristopher Josephson